218 related articles for article (PubMed ID: 17627467)
1. Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells.
Kurtoglu M; Maher JC; Lampidis TJ
Antioxid Redox Signal; 2007 Sep; 9(9):1383-90. PubMed ID: 17627467
[TBL] [Abstract][Full Text] [Related]
2. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation.
Kurtoglu M; Gao N; Shang J; Maher JC; Lehrman MA; Wangpaichitr M; Savaraj N; Lane AN; Lampidis TJ
Mol Cancer Ther; 2007 Nov; 6(11):3049-58. PubMed ID: 18025288
[TBL] [Abstract][Full Text] [Related]
3. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions.
Maher JC; Krishan A; Lampidis TJ
Cancer Chemother Pharmacol; 2004 Feb; 53(2):116-22. PubMed ID: 14605866
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells".
Lampidis TJ; Kurtoglu M; Maher JC; Liu H; Krishan A; Sheft V; Szymanski S; Fokt I; Rudnicki WR; Ginalski K; Lesyng B; Priebe W
Cancer Chemother Pharmacol; 2006 Dec; 58(6):725-34. PubMed ID: 16555088
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose.
Maher JC; Wangpaichitr M; Savaraj N; Kurtoglu M; Lampidis TJ
Mol Cancer Ther; 2007 Feb; 6(2):732-41. PubMed ID: 17308069
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression.
Maher JC; Savaraj N; Priebe W; Liu H; Lampidis TJ
Pancreas; 2005 Mar; 30(2):e34-9. PubMed ID: 15714127
[TBL] [Abstract][Full Text] [Related]
7. Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia.
Gu L; Yi Z; Zhang Y; Ma Z; Zhu Y; Gao J
Oncotarget; 2017 May; 8(19):30978-30991. PubMed ID: 28415682
[TBL] [Abstract][Full Text] [Related]
8. Reassessment of FDG uptake in tumor cells: high FDG uptake as a reflection of oxygen-independent glycolysis dominant energy production.
Waki A; Fujibayashi Y; Yonekura Y; Sadato N; Ishii Y; Yokoyama A
Nucl Med Biol; 1997 Oct; 24(7):665-70. PubMed ID: 9352538
[TBL] [Abstract][Full Text] [Related]
9. 2-Deoxy-D-glucose Restore Glucocorticoid Sensitivity in Acute Lymphoblastic Leukemia via Modification of N-Linked Glycosylation in an Oxygen Tension-Independent Manner.
Leni Z; Ćwiek P; Dimitrova V; Dulcey AS; Zamboni N; Simillion C; Rossi G; Leibundgut K; Arcaro A
Oxid Med Cell Longev; 2017; 2017():2487297. PubMed ID: 28814986
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia.
DeSalvo J; Kuznetsov JN; Du J; Leclerc GM; Leclerc GJ; Lampidis TJ; Barredo JC
Mol Cancer Res; 2012 Jul; 10(7):969-78. PubMed ID: 22692960
[TBL] [Abstract][Full Text] [Related]
11. Separate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells.
Xiao H; Li S; Zhang D; Liu T; Yu M; Wang F
Oncol Rep; 2013 Jan; 29(1):329-34. PubMed ID: 23076497
[TBL] [Abstract][Full Text] [Related]
12. Short-term exposure of multicellular tumor spheroids of a human glioma cell line to the glycolytic inhibitor 2-deoxy-D-glucose is more toxic than continuous exposure.
Khaitan D; Chandna S; Dwarakanath SB
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S67-73. PubMed ID: 20009299
[TBL] [Abstract][Full Text] [Related]
13. Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells.
Berthe A; Zaffino M; Muller C; Foulquier F; Houdou M; Schulz C; Bost F; De Fay E; Mazerbourg S; Flament S
Breast Cancer Res Treat; 2018 Oct; 171(3):581-591. PubMed ID: 29971627
[TBL] [Abstract][Full Text] [Related]
14. Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.
Singh S; Pandey S; Bhatt AN; Chaudhary R; Bhuria V; Kalra N; Soni R; Roy BG; Saluja D; Dwarakanath BS
PLoS One; 2015; 10(7):e0132089. PubMed ID: 26135741
[TBL] [Abstract][Full Text] [Related]
15. The proliferative response of hela cells to 2-deoxy-D-glucose under hypoxic or anoxic conditions: an analogue for studying some properties of in vivo solid cancers.
Anderson KM; Tsui P; Guinan P; Rubenstein M
Anticancer Res; 2006; 26(6B):4155-62. PubMed ID: 17201127
[TBL] [Abstract][Full Text] [Related]
16. In vitro effects of dichloroacetate and CO2 on hypoxic HeLa cells.
Anderson KM; Jajeh J; Guinan P; Rubenstein M
Anticancer Res; 2009 Nov; 29(11):4579-88. PubMed ID: 20032407
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity of high dose ascorbic acid is enhanced by 2-deoxy-d-glucose in glycolytic melanoma cells.
Hill-Mündel K; Nohr D
Biochem Biophys Res Commun; 2021 Mar; 546():90-96. PubMed ID: 33578294
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-Induced increase in FDG uptake in MCF7 cells.
Burgman P; Odonoghue JA; Humm JL; Ling CC
J Nucl Med; 2001 Jan; 42(1):170-5. PubMed ID: 11197971
[TBL] [Abstract][Full Text] [Related]
19. Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms.
Laussel C; Léon S
Biochem Pharmacol; 2020 Dec; 182():114213. PubMed ID: 32890467
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic activity of 2-deoxy-D-glucose.
Merchan JR; Kovács K; Railsback JW; Kurtoglu M; Jing Y; Piña Y; Gao N; Murray TG; Lehrman MA; Lampidis TJ
PLoS One; 2010 Oct; 5(10):e13699. PubMed ID: 21060881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
